Leukemia & Lymphoma最新文献_第7页

Drug exposure and measurable residual disease in chronic lymphocytic leukemia: a systematic review. 慢性淋巴细胞白血病的药物暴露与可测量残留病：系统综述。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-02-01 Epub Date: 2024-11-07 DOI: 10.1080/10428194.2024.2412289

Cathrine Korsholm, Cille Bülow, Mikkel Christensen, Kim Dalhoff, Joshua Buron Feinberg, Trine Meldgaard Lund, Carsten Utoft Niemann, Tonny Studsgaard Petersen, Michael Asger Andersen

{"title":"Drug exposure and measurable residual disease in chronic lymphocytic leukemia: a systematic review.","authors":"Cathrine Korsholm, Cille Bülow, Mikkel Christensen, Kim Dalhoff, Joshua Buron Feinberg, Trine Meldgaard Lund, Carsten Utoft Niemann, Tonny Studsgaard Petersen, Michael Asger Andersen","doi":"10.1080/10428194.2024.2412289","DOIUrl":"10.1080/10428194.2024.2412289","url":null,"abstract":"For fixed-duration therapies against chronic lymphocytic leukemia (CLL), undetectable measurable residual disease (MRD) predicts overall and progression-free survival more accurately than complete remission. For indefinite therapies, MRD status can direct discontinuation of treatment. We systematically reviewed the relationship between antineoplastic drug exposures and undetectable MRD in CLL. Seventeen trials from MEDLINE and EMBASE met the inclusion criteria; four of which evaluated drug exposures in relation to MRD status. Undetectable MRD was associated with higher trough concentrations of ofatumumab and alemtuzumab, as well as increased maximum concentration and area under the plasma concentration curve (AUC) of ibrutinib. One study found an association between high rituximab AUC and undetectable MRD until adjusting for tumor burden. The limited studies, lack of exposure measurements of concomitant drugs, and high heterogeneity in designs limit the results' generalizability. Further research is needed to explore the exposure-MRD relationship and the possibility for therapeutic drug monitoring in CLL.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"229-239"},"PeriodicalIF":2.2,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142604917","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

FDA-approved disulfiram induces ferroptosis via alteration of redox balance and lipid peroxidation and overcomes carfilzomib resistance in multiple myeloma. 美国 FDA 批准的双硫仑可通过改变氧化还原平衡和脂质过氧化诱导铁变态反应，并克服多发性骨髓瘤患者对卡非佐米的耐药性。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-02-01 Epub Date: 2024-11-11 DOI: 10.1080/10428194.2024.2422843

Caglar Arkan, Dilara Akcora-Yildiz

{"title":"FDA-approved disulfiram induces ferroptosis via alteration of redox balance and lipid peroxidation and overcomes carfilzomib resistance in multiple myeloma.","authors":"Caglar Arkan, Dilara Akcora-Yildiz","doi":"10.1080/10428194.2024.2422843","DOIUrl":"10.1080/10428194.2024.2422843","url":null,"abstract":"Multiple myeloma (MM), a malignant plasma cell disorder, remains incurable due to inevitable chemo-resistance development, including carfilzomib (CFZ) leading to relapse and poor patient outcomes. Therefore, new treatment strategies, including using FDA-approved alcohol deterrent disulfiram (DSF) are under investigation. The present study investigated the effect of DSF on ferroptosis and CFZ resistance in MM cells. Our findings indicate that DSF increases the production of cytosolic and mitochondrial reactive oxygen species, and causes a loss of mitochondrial Δψ and an elevation in lipid peroxidation in MM cells. DSF treatment in MM cell lines led to the significant downregulation of ferroptotic genes, including glutathione peroxidase 4. Moreover, ferroptosis inhibitor liproxstatin-1rescued DSF-induced ferroptosis by promoting glutathione peroxidase 4 upregulation. DSF alone overcomes CFZ resistance through lipid peroxidation elevation and acts synergistically with CFZ in CFZ-resistant MM cell lines. Our results suggest that DSF is a promising anti-myeloma agent for overcoming CFZ resistance in MM through ferroptosisinduction.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"250-261"},"PeriodicalIF":2.2,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142622848","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

MicroRΝΑ analysis in patients with myelodysplastic neoplasms. Possible implications in risk stratification. 骨髓增生异常肿瘤患者的 MicroRΝΑ 分析。对风险分层的可能影响。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-02-01 Epub Date: 2024-10-08 DOI: 10.1080/10428194.2024.2412291

Stavroula Syriopoulou, Christina-Nefeli Kontandreopoulou, Panagiotis T Diamantopoulos, Dimitra Vlachopoulou, Christos Stafylidis, Panagiota Katsiampoura, Sevastianos Chatzidavid, Nefeli Giannakopoulou, Vassiliki Pappa, Ioannis Kotsianidis, Eleftheria Hatzimichael, Maria Dimou, Argiris Symeonidis, Panayiotis Panayiotidis, Nora-Athina Viniou

{"title":"MicroRΝΑ analysis in patients with myelodysplastic neoplasms. Possible implications in risk stratification.","authors":"Stavroula Syriopoulou, Christina-Nefeli Kontandreopoulou, Panagiotis T Diamantopoulos, Dimitra Vlachopoulou, Christos Stafylidis, Panagiota Katsiampoura, Sevastianos Chatzidavid, Nefeli Giannakopoulou, Vassiliki Pappa, Ioannis Kotsianidis, Eleftheria Hatzimichael, Maria Dimou, Argiris Symeonidis, Panayiotis Panayiotidis, Nora-Athina Viniou","doi":"10.1080/10428194.2024.2412291","DOIUrl":"10.1080/10428194.2024.2412291","url":null,"abstract":"MiRNAs have been identified as participants in leukemogenesis by controlling several cellular functions, such as differentiation, proliferation, and apoptosis. Their role in myelodysplastic neoplasms (MDS) pathogenesis is researched due to implementations in early identification, classification, and therapeutical options. IPSS-R, being the most widely used MDS classification, underestimates early biological events that can alter the disease's prognosis. The purpose of this study is to determine whether miRNA levels are aligned to MDS risk stratification groups and can therefore be used as diagnostic biomarkers. To evaluate miRNAs as possible biomarkers, we measured the levels of miR-181a-2-3p, miR-124-3p, miR-550a-3p, miR-155-5p, miR-151a-3p, and miR-125b-5p by a quantitative real-time PCR in bone marrow samples of 41 MDS patients. In conclusion, in myeloid malignancies, genomic characteristics may provide a wider apprehension of its clinical course and prognosis. MiRNAs constitute a possible diagnostic biomarker and therapeutic target, allowing intermediate-risk patients that express high levels of specific miRNAs to be re-classified and receive more advanced therapeutic agents. In our study, an association between high levels of miRNAs and worsening outcomes is established, supporting the need for further incorporation of molecular data into currently used classification systems.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"313-319"},"PeriodicalIF":2.2,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142391628","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

High Ki67 index is associated with shorter progression free survival in patients with Follicular Lymphoma treated with frontline immunochemotherapy. 在接受前线免疫化疗的滤泡性淋巴瘤患者中，高Ki67指数与较短的无进展生存期有关。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-02-01 Epub Date: 2024-10-16 DOI: 10.1080/10428194.2024.2414899

Jianmin Han, Chad M McCall, Scott Isom, Wesley Matthew Smith, Stephanie Begley, Dakota Jenneman, Rupali Bose, Mary Beth Seegars, Eric D Hsi, Nilanjan Ghosh

引用次数: 0

Adoptive cell therapy in acute myeloid leukemia: the current landscape and emerging strategies. 急性髓性白血病的适应性细胞疗法：当前形势与新兴策略。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-02-01 Epub Date: 2024-10-25 DOI: 10.1080/10428194.2024.2414112

Serena Tharakan, Douglas Tremblay, Jacques Azzi

引用次数: 0

Analyzing determinants of premature trial discontinuation in leukemia clinical trials. 分析白血病临床试验中过早终止试验的决定因素。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-02-01 Epub Date: 2024-10-23 DOI: 10.1080/10428194.2024.2416565

Lara K Rotter, Abdulrahman Alhajahjeh, Jessica M Stempel, Alyssa A Grimshaw, Jan Philipp Bewersdorf, Ondrej Blaha, Tariq Kewan, Nikolai A Podoltsev, Rory M Shallis, Lourdes Mendez, Maximilian Stahl, Amer M Zeidan

{"title":"Analyzing determinants of premature trial discontinuation in leukemia clinical trials.","authors":"Lara K Rotter, Abdulrahman Alhajahjeh, Jessica M Stempel, Alyssa A Grimshaw, Jan Philipp Bewersdorf, Ondrej Blaha, Tariq Kewan, Nikolai A Podoltsev, Rory M Shallis, Lourdes Mendez, Maximilian Stahl, Amer M Zeidan","doi":"10.1080/10428194.2024.2416565","DOIUrl":"10.1080/10428194.2024.2416565","url":null,"abstract":"Clinical trials are crucial for improving patient outcomes. Although a significant number of trials are discontinued prematurely, our understanding of factors influencing early termination is limited. We conducted a comprehensive search of ClinicalTrials.gov to identify leukemia trials from 2000 to 2020, followed by data abstraction performed by two independent reviewers. Among 3522 leukemia clinical trials identified, 28.4% were terminated prematurely. Slow accrual was the leading cause of termination 38.2%. The termination rate increased significantly from 17.0% between 2000 and 2005 to 30.9% between 2010 and 2015 (p < .001). Large trials had a lower termination rate than small trials (p < .001). Academic-sponsored trials had the highest termination rates compared to other sponsors' trials (p < .001). Early-phase trials showed higher termination rates compared to late-phase (p < .001). Other significant factors included a sequential assignment, single-center, and non-randomized trials (p < .001). Much of leukemia trials are terminated prematurely, with slow accrual being the most common reason for early termination.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"289-297"},"PeriodicalIF":2.2,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142503147","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Indolent lymphoma: addressing the needs of survivors.

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-01-28 DOI: 10.1080/10428194.2025.2456970

Pasquale L Fedele, Stephen Opat

{"title":"Indolent lymphoma: addressing the needs of survivors.","authors":"Pasquale L Fedele, Stephen Opat","doi":"10.1080/10428194.2025.2456970","DOIUrl":"10.1080/10428194.2025.2456970","url":null,"abstract":"Over the past two decades, there has been a continuous improvement in outcome for patients with indolent lymphoma (iNHL) resulting in a gradual accumulation of survivors. While life expectancy in the current era approaches that of the lymphoma-free population, patients continue to experience lifelong complications of the disease and its treatment affecting general health, emotional, psychological and social wellbeing, relationships, employment, finances, and fitness. Contemporary care models while suited to the management of lymphoma are often lacking when it comes to identification and management of these additional needs. Given improvements in physical survival achieved over the past decades, it is timely for us to focus on other issues affecting patient wellbeing including immunodeficiency and infection, second cancers, cardiovascular disease, bone health, psychological wellbeing, and sexual health. Many of these aspects are in the domain of the primary care physician; however, there is limited guidance on how these issues should be addressed. It is now time for us to engage our patients, their caregivers, and other healthcare providers in care aspects beyond the lymphoma diagnosis, so they can anticipate a rich and full life, free from both direct and indirect consequences of the lymphoma diagnosis.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-15"},"PeriodicalIF":2.2,"publicationDate":"2025-01-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143059824","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Polatuzumab vedotin extravasation injury: a case report.

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-01-25 DOI: 10.1080/10428194.2025.2456092

Sushila A Toulmin, Hana I Nazir, Jeremy S Abramson, Jacob D Soumerai, Esther E Freeman

引用次数: 0

Presence of minimal residual disease determined by next-generation sequencing is not a reliable prognostic biomarker in children with acute lymphoblastic leukemia.

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-01-22 DOI: 10.1080/10428194.2025.2456100

Elizabeta Krstevska Bozhinovikj, Nadica Matevska-Geshkovska, Marija Staninova Stojovska, Emilija Gjorgievska, Aleksandra Jovanovska, Nevenka Ridova, Irina Panovska Stavridis, Svetlana Kocheva, Aleksandar Dimovski

{"title":"Presence of minimal residual disease determined by next-generation sequencing is not a reliable prognostic biomarker in children with acute lymphoblastic leukemia.","authors":"Elizabeta Krstevska Bozhinovikj, Nadica Matevska-Geshkovska, Marija Staninova Stojovska, Emilija Gjorgievska, Aleksandra Jovanovska, Nevenka Ridova, Irina Panovska Stavridis, Svetlana Kocheva, Aleksandar Dimovski","doi":"10.1080/10428194.2025.2456100","DOIUrl":"https://doi.org/10.1080/10428194.2025.2456100","url":null,"abstract":"The role of next-generation sequencing (NGS) for minimal residual disease (MRD) assessment in pediatric acute lymphoblastic leukemia (ALL) is still under consideration. Fifty pediatric patients were prospectively evaluated for specific clonal rearrangements of immunoglobulin and T-cell receptor genes using NGS analysis at diagnosis and on days 33 and 78 from therapy onset. The prognostic value or the NGS-MRD status was analyzed after a median follow-up of 4 years. All but one patient with negative NGS-MRD status on day 33 are in clinical remission. A total of 29 (58%) patients were NGS-MRD positive on day 33, of which 9 (18%) patients remained positive on day 78. However, only a small percentage of the patients with positive NGS-MRD status on day 33 and day 78 relapsed: 21% (6/29) and 33% (3/9), respectively. Positive NGS-MRD status is not a reliable prognostic biomarker in children with ALL and warrants careful consideration in disease stratification.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-8"},"PeriodicalIF":2.2,"publicationDate":"2025-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143024024","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Therapeutic approach to patients with early stage diffuse large B cell lymphoma: retrospective, multicenter, real-life study of the 'RTL' (regional Tuscan lymphoma network). 早期弥漫性大B细胞淋巴瘤患者的治疗方法：托斯卡纳区域淋巴瘤网络（RTL）的回顾性、多中心、现实研究

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-01-21 DOI: 10.1080/10428194.2025.2456094

Emanuele Cencini, Marianna Palazzo, Dimitri Dardanis, Giulia Lucco Navei, Lara Mannelli, Valentina Zoi, Bianca Mecacci, Benedetta Sordi, Giulia Cervetti, Serena Rosati, Luca Nassi, Monica Bocchia, Alberto Fabbri

{"title":"Therapeutic approach to patients with early stage diffuse large B cell lymphoma: retrospective, multicenter, real-life study of the 'RTL' (regional Tuscan lymphoma network).","authors":"Emanuele Cencini, Marianna Palazzo, Dimitri Dardanis, Giulia Lucco Navei, Lara Mannelli, Valentina Zoi, Bianca Mecacci, Benedetta Sordi, Giulia Cervetti, Serena Rosati, Luca Nassi, Monica Bocchia, Alberto Fabbri","doi":"10.1080/10428194.2025.2456094","DOIUrl":"https://doi.org/10.1080/10428194.2025.2456094","url":null,"abstract":"Treatment strategies for early stage diffuse large B-cell lymphoma (ES-DLBCL) include R-CHOP, with a similar schedule to that used in advanced stage, or a reduced number of cycles followed by radiation therapy (RT). We retrospectively analyzed 179 ES-DLBCL patients, managed according to the clinical practice. Treatment regimens include chemoimmunotherapy 4-6 cycles +/- RT as consolidation. First-line therapy was R-CHOP/CHOP-like in 88.8% of cases. RT as consolidation was administered to 29.9% of cases. Complete response rate was 87.2%, median PFS and OS were not reached. IPI 2-3 and first-line regimen with 3-4 cycles of R-CHOP without RT were the 2 prognostic variables for OS in multivariate analysis. After a median follow-up of 48 months, 31 patients died (17.3%). We suggest that both R-CHOP 6 cycles and 3-4 cycles followed by RT as consolidation seem to be valid first-line regimens, while an abbreviated strategy without RT could be associated to inferior outcome.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-10"},"PeriodicalIF":2.2,"publicationDate":"2025-01-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143007803","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0